Irhythm Technologies (NASDAQ: IRTC) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Irhythm Technologies to similar companies based on the strength of its dividends, valuation, earnings, risk, institutional ownership, analyst recommendations and profitability.
This table compares Irhythm Technologies and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Irhythm Technologies Competitors||-62.26%||-47.35%||-18.28%|
This table compares Irhythm Technologies and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Irhythm Technologies||$98.51 million||-$29.42 million||-47.95|
|Irhythm Technologies Competitors||$1.54 billion||$111.80 million||-145.38|
Irhythm Technologies’ peers have higher revenue and earnings than Irhythm Technologies. Irhythm Technologies is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
98.6% of Irhythm Technologies shares are held by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 23.3% of Irhythm Technologies shares are held by company insiders. Comparatively, 15.7% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent recommendations and price targets for Irhythm Technologies and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Irhythm Technologies Competitors||493||1888||3754||117||2.56|
Irhythm Technologies currently has a consensus price target of $71.17, suggesting a potential upside of 14.16%. As a group, “Surgical & medical instruments” companies have a potential upside of 12.78%. Given Irhythm Technologies’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Irhythm Technologies is more favorable than its peers.
Risk and Volatility
Irhythm Technologies has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Irhythm Technologies’ peers have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.
Irhythm Technologies beats its peers on 8 of the 12 factors compared.
About Irhythm Technologies
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.